Neoadjuvant and adjuvant treatment-related adverse events
| Neoadjuvant treatment (N=36) | Adjuvant treatment (N=31) | |||
| Any grade | Grade 3 | Any grade | Grade 3 | |
| Treatment-related AEs, n (%) | 33 (91.7) | 10 (27.8) | 28 (90.3) | 2 (6.5) |
| Anemia | 26 (72.2) | 5 (13.9) | 5 (16.1) | 0 |
| White blood cell count decrease | 18 (50.0) | 1 (2.8) | 20 (64.5) | 0 |
| Neutrophil count decrease | 15 (41.7) | 5 (13.9) | 20 (64.5) | 2 (5.6) |
| Vomiting | 10 (27.8) | 0 | 9 (29.0) | 1 (2.8) |
| Alanine aminotransferase increase | 7 (19.4) | 0 | 3 (9.7) | 0 |
| Aspartate aminotransferase increase | 7 (19.4) | 1 (2.8) | 4 (12.9) | 0 |
| Hypokalemia | 6 (16.7) | 0 | 3 (9.7) | 0 |
| Platelet count decrease | 6 (16.7) | 1 (2.8) | 6 (19.4) | 0 |
| Gamma-glutamyl transferase increase | 4 (11.1) | 1 (2.8) | 5 (16.1) | 0 |
| Constipation | 3 (8.3) | 0 | 0 | 0 |
| Fever | 3 (8.3) | 0 | 0 | 0 |
| Rash | 3 (8.3) | 0 | 0 | 0 |
| Hypophagia | 2 (5.6) | 0 | 2 (6.5) | 0 |
| Hyperthyroidism | 2 (5.6) | 0 | 0 | 0 |
| Urinary tract infection | 1 (2.8) | 0 | 0 | 0 |
| Nausea | 1 (2.8) | 0 | 1 (3.2) | 0 |
| Lymphocyte count decrease | 1 (2.8) | 0 | 0 | 0 |
| Hypothyroidism | 1 (2.8) | 0 | 3 (9.7) | 0 |
| Enteritis | 1 (2.8) | 0 | 0 | 0 |
| Dermatitis allergic | 1 (2.8) | 0 | 0 | 0 |
| Lower gastrointestinal hemorrhage | 0 | 0 | 1 (3.2) | 0 |
| Palmar–plantar erythrodysesthesia syndrome | 0 | 0 | 1 (3.2) | 0 |
| Diarrhea | 0 | 0 | 1 (3.2) | 0 |
| Blood alkaline phosphatase increase | 0 | 0 | 1 (3.2) | 0 |
| Immune-related AEs, n (%) | 1 (2.8) | 0 | 0 | 0 |
| Hyperthyroidism | 2 (5.6) | 0 | 0 | 0 |
| Hypothyroidism | 1 (2.8) | 0 | 0 | 0 |
AEs, adverse events.